GenSight Biologics S.A.
SIGHT
Rank in Stocks
#27619
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Share Price
$0.08686381
Last synced: 2026-11-09
Market Cap
$14.16M
Change (1 day)
12.60%
Change (1 year)
-34.52%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GenSight Biologics S.A. (SIGHT)
Category
Healthcare
EPS for GenSight Biologics S.A. (SIGHT)
EPS as of June 2026 TTM: $-0.08
According to GenSight Biologics S.A.'s latest financial reports, its current EPS (TTM) is $-0.08. At the end of 2025 the company had an EPS of $-0.10, an increase over its 2024 EPS of $-0.16.
EPS history for GenSight Biologics S.A. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.08 | -18.80% |
| 2025 | $-0.10 | -38.95% |
| 2024 | $-0.16 | -73.85% |
| 2023 | $-0.60 | -7.24% |
| 2022 | $-0.64 | -10.16% |
| 2021 | $-0.72 | -39.35% |
| 2020 | $-1.18 | -2.51% |
| 2019 | $-1.21 | -23.03% |
| 2018 | $-1.57 | 19.27% |
| 2017 | $-1.32 | -7.76% |
| 2016 | $-1.43 | 8.92% |
| 2015 | $-1.31 | 44.77% |
| 2014 | $-0.91 | 106.20% |
| 2013 | $-0.44 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -19,385.71% |
US
|
|
| $-7.07 | 8,606.90% |
US
|
|
| $-5.29 | 6,414.78% |
AU
|
|
| $12.88 | -15,962.19% |
BE
|
|
| $21.56 | -26,651.72% |
NL
|
Questions about GenSight Biologics S.A.'s earnings per share (EPS)
What is GenSight Biologics S.A.'s earnings per share (EPS)?
GenSight Biologics S.A.'s earnings per share (EPS) over the last twelve months is $-0.08, as of Jun 2026.
What was GenSight Biologics S.A.'s earnings per share (EPS) in 2025?
In 2025, GenSight Biologics S.A.'s earnings per share (EPS) was $-0.10, compared with $-0.16 in 2024.
How has GenSight Biologics S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, GenSight Biologics S.A.'s earnings per share (EPS) was highest in 2025 ($-0.10) and lowest in 2020 ($-1.18).
How does GenSight Biologics S.A.'s earnings per share (EPS) compare with similar companies?
GenSight Biologics S.A.'s earnings per share (EPS) ($-0.08) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.